# Plasmalogens

Rating: Promising — Some human trials, or consistent animal work with a clear mechanism
Type: Compound
Updated: 2026-08-06
Canonical: https://heretic.bio/articles/plasmalogens-and-membrane-health.html

> Plasmalogens are membrane phospholipids whose vinyl-ether bond makes them sacrificial antioxidants; they concentrate in brain and heart and fall steeply after age 50. Low blood levels robustly predict cognitive decline in cohort data including Framingham. The intervention evidence is much thinner: one open-label trial of a DHA precursor (n=22) raised blood plasmalogens dose-dependently and 41% of participants improved on the CDR scale, but there is no placebo-controlled trial, and the FDA warned the lead researcher's clinic in 2025 for studying supplements without an IND.

> **Core thesis:** Plasmalogens are a specialized class of phospholipids with a unique vinyl-ether bond at the sn-1 position, enriched in brain, heart, and immune cell membranes. They function as endogenous antioxidants, membrane structure modulators, and signaling molecule precursors. Blood and brain plasmalogen levels decline precipitously with age — particularly after age 50 — and this decline is strongly associated with cognitive decline, neurodegenerative disease (especially Alzheimer's and Parkinson's), sarcopenia, and cardiovascular disease. Targeted plasmalogen supplementation with DHA-enriched precursors has shown dose-dependent restoration of blood plasmalogen levels, improvement in oxidative stress biomarkers, and preliminary cognitive/mobility benefits in clinical trials.

* * *

## Biochemistry of Plasmalogens

### Structure

Plasmalogens are a subclass of **glycerophospholipids** distinguished by a **vinyl-ether bond** at the sn-1 position of the glycerol backbone (vs. the ester bond in conventional phospholipids).

Feature | Plasmalogens (Pls) | Phosphatidyl-Lipids (Ptd)  
---|---|---  
**sn-1 bond** | Vinyl-ether (alk-1-enyl) | Ester (acyl)  
**sn-2 fatty acid** | Typically DHA or AA (PUFA) | Variable  
**sn-3 head group** | Ethanolamine (PlsEtn) or Choline (PlsCho) | Ethanolamine or Choline  
**Key property** | Vinyl-ether bond is a sacrificial antioxidant target | Standard membrane lipid  
  
### Types

  * **Ethanolamine plasmalogens (PlsEtn):** ~80% of total plasmalogens; enriched in brain, heart, skeletal muscle. The predominant form relevant to neurodegeneration.
  * **Choline plasmalogens (PlsCho):** ~20%; enriched in heart and lung surfactant.



### Biosynthesis

Plasmalogen synthesis occurs in **peroxisomes** (initial steps) and **endoplasmic reticulum** (completion):

  1. **Dihydroxyacetone phosphate (DHAP)** \+ acyl-CoA → acyl-DHAP (peroxisomal acyltransferase)
  2. **Alkyl-DHAP synthase** replaces the acyl group with a fatty alcohol → alkyl-DHAP (peroxisome)
  3. Import to ER; further modifications: reduction, acylation at sn-2, desaturation to create vinyl-ether bond
  4. Final products: PlsEtn with DHA at sn-2 (the predominant brain species)



> **Clinical significance:** Peroxisomal disorders (e.g., Zellweger syndrome) cause severe plasmalogen deficiency, confirming the peroxisomal dependence and the critical role of plasmalogens in neural development.

### Tissue Distribution

Tissue | Plasmalogen Content | Notes  
---|---|---  
**Brain** | Very high (up to 30% of ethanolamine phospholipids) | Myelin sheaths, synaptic membranes  
**Heart** | High | Mitochondrial membranes,导电 cells  
**Skeletal muscle** | Moderate | Mitochondrial function  
**Immune cells** | Moderate | Macrophage/lymphocyte membranes  
**Erythrocytes** | Moderate | Easily measured as blood biomarker  
  
* * *

## Functions of Plasmalogens

### 1\. Endogenous Antioxidant (Primary)

The **vinyl-ether bond** is uniquely susceptible to oxidation by reactive oxygen species (ROS). This makes plasmalogens **sacrificial scavengers** :

  * Plasmalogen vinyl-ether bond + ROS → oxidized plasmalogen (inert) + H₂O
  * This reaction **protects adjacent polyunsaturated fatty acids** (DHA, AA) from peroxidation
  * Plasmalogens are the **first line of defense** against membrane lipid peroxidation
  * Without sufficient plasmalogens, DHA and AA in membranes undergo uncontrolled oxidative damage



**Evidence:** Sindelar et al. (1999) demonstrated that plasmalogen vinyl-ether bonds react with ROS at rates 10-100× faster than PUFAs, confirming their sacrificial antioxidant role.

### 2\. Membrane Structure and Fluidity

  * Plasmalogens have a **smaller head group** than phosphatidyl lipids, creating tighter packing in the membrane
  * This affects membrane **fluidity, curvature, and fusion capacity**
  * Critical for **vesicle formation and neurotransmitter release** in neurons
  * Essential for **myelin sheath integrity** and conduction velocity



### 3\. Cholesterol Metabolism Regulation

Plasmalogens modulate HDL-mediated cholesterol transport: \- DHA-plasmalogens dose-dependently **increase cholesterol esterification** via acyl-CoA acetyltransferase (ACAT) \- They **reduce free cholesterol** in membranes \- This may explain the association between low plasmalogens and atherosclerosis

### 4\. Amyloid Pathway Modulation

  * Increasing membrane DHA-plasmalogen levels **upregulates alpha-secretase** (non-amyloidogenic APP processing)
  * Results in **decreased Aβ 1-42** production (the toxic amyloid species)
  * DHA-plasmalogen precursor blocks the increase in Aβ 1-42 caused by cholesterol loading (Wood et al., 2011)



### 5\. Neurotransmission and Synaptic Function

  * Plasmalogens are enriched in **synaptic vesicle membranes**
  * Required for efficient **vesicle fusion and neurotransmitter release**
  * Low plasmalogens impair cholinergic neurotransmission (relevant to Alzheimer's)
  * Oral plasmalogen supplementation in mice increased **hippocampal BDNF expression** (Hossain et al., 2022)



### 6\. Immune Function

  * Plasmalogens are precursors to **platelet-activating factor (PAF)** and **eicosanoids**
  * Macrophage plasmalogen content influences phagocytosis efficiency
  * Low plasmalogens associated with chronic inflammatory states



* * *

## Plasmalogen Decline in Aging and Disease

### Age-Related Decline

Plasmalogen levels follow a predictable lifecycle pattern:

Age Range | Plasmalogen Level | Significance  
---|---|---  
**0-30** | Increasing to peak | Brain development, maturation  
**30-40** | Plateau / slow decline | Optimal levels  
**40-50** | Decline begins | Subclinical  
**50-70** | **Steep decline** | Cognitive vulnerability increases  
**70+** | Severely depleted | ~40% reduction from peak (Rouser & Yamamoto, 1968)  
  
This decline is driven by: \- Decreased peroxisomal function with age \- Increased oxidative stress consuming plasmalogens as sacrificial antioxidants \- Reduced biosynthetic enzyme activity \- Cumulative free radical damage to existing plasmalogen pool

### Association with Neurodegenerative Disease

The association between low plasmalogens and cognitive decline is described as **"robust and reproducible"** across dozens of studies:

Disease | Plasmalogen Finding | Key Reference  
---|---|---  
**Alzheimer's disease** | 30-40% reduction in brain DHA-plasmalogens | Goodenowe et al. 2007 (Framingham Study, n=1,800+)  
**Parkinson's disease** | Reduced plasmalogens in substantia nigra | Goodenowe 2021; Wu et al. 2024 (nasal plasmalogen nano-medicine)  
**Multiple sclerosis** | Decreased myelin plasmalogens | Dorninger et al. 2017  
**Age-related cognitive decline** | Blood DHA-plasmalogen levels predict cognitive function | Kling et al. 2020; Lim et al. 2020  
  
> **Framingham Heart Study:** Goodenowe et al. analyzed plasmalogen levels in blood from the Framingham cohort (n>1,800). Low blood DHA-plasmalogen levels were **predictive of future cognitive decline** — even decades before symptom onset. This is among the strongest epidemiological evidence for plasmalogens as a biomarker.

### Association with Sarcopenia and Mobility

  * Reduced blood DHA-plasmalogen levels correlate with **decreased grip strength** and **slower gait speed**
  * Plasmalogen-deficient mice show neuromuscular junction defects (Dorninger et al. 2017)
  * Sarcopenia prevalence is ~3× higher in persons with dementia vs. without (Pacifico et al. 2020), suggesting shared plasmalogen-dependent mechanism



* * *

## Doses in studies

### Goodenowe et al. 2022 (_Frontiers in Cell and Developmental Biology_)

**Citation:** Goodenowe DB, Haroon J, Kling MA, et al. "Targeted plasmalogen supplementation: Effects on blood plasmalogens, oxidative stress biomarkers, cognition, and mobility in cognitively impaired persons." _Front Cell Dev Biol_. 2022;10:864842. doi:[10.3389/fcell.2022.864842](https://doi.org/10.3389/fcell.2022.864842). PMID: [35874835](https://pubmed.ncbi.nlm.nih.gov/35874835/). NCT: [NCT04484454](https://clinicaltrials.gov/study/NCT04484454)

#### Study Design

  * **Participants:** 22 cognitively impaired persons (CDR 0.5-3), ages 37-84 (mean 67)
  * **Intervention:** Oral DHA-AAG (1-O-alkyl-2-acylglycerol with DHA at sn-2), a synthetic plasmalogen precursor
  * **Dosing schedule (escalating):**
  * **Product:** ProdromeSciences DHA-AAG; C16:C18 alkylglycerol backbone (chimyl/batyl alcohol), >95% DHA at sn-2/sn-3, algae-derived, purity >98%



#### Key Results

**Pharmacokinetics (Blood DHA-Plasmalogen Levels):** \- DHA-plasmalogen levels increased **dose-dependently** \- Significant elevation at all doses and time points (p<0.05 vs. baseline) \- Direct target (DHA-PL) increased more than indirect targets (DHA-PE, LA/AA-PL) \- No effect on biochemically unrelated species ((LA+AA)-PE) — confirming specificity \- Levels declined during washout month but remained above baseline

**Oxidative Stress Biomarkers:**

Biomarker | Effect | Significance  
---|---|---  
**Malondialdehyde (MDA)** | ↓ Decreased | Lipid peroxidation reduced (correlated with DHA-PL levels)  
**Catalase (CAT)** | ↑ Increased | Hydrogen peroxide neutralization improved  
**Superoxide dismutase (SOD)** | Normalized | Reduced in those with high baseline SOD  
  
  * DHA-PL levels were **positively associated** with catalase activity (p=0.0022)
  * DHA-PL levels were **negatively associated** with MDA (p=0.033)
  * Plasmalogens normalized oxidant/antioxidant balance in both directions



**Cognitive Outcomes (CDR scale):**

Outcome | Participants | Percentage  
---|---|---  
Improved (≥1 CDR unit change) | 9/22 | 41%  
Unchanged | 9/22 | 41%  
Declined | 4/22 | 18%  
  
**Mobility Outcomes (30-sec Sit/Stand):**

Outcome | Participants | Percentage  
---|---|---  
Improved (≥2 repetitions) | 12/22 | 55%  
Unchanged | 5/22 | 23%  
Declined | 4/22 | 18%  
  
**Critical Assessment:** \- No placebo group — this was an **open-label investigational trial** \- 41% improvement rate is meaningful but **41% unchanged and 18% declined** \- Baseline DHA-plasmalogen levels were **not predictive** of clinical response \- Cognition improvement was statistically significant vs. random outcome probability \- Authors note product was well tolerated with no adverse reactions

### Other Clinical Studies

Study | Design | Key Finding | Citation  
---|---|---|---  
**Fujino et al. 2017** | RCT, healthy adults, plasmalogen supplement | Improved cognition and mood; 2g/day dose | _J Oleo Sci_  
**Fujino et al. 2018** | Follow-up study | Confirmed cognitive benefit in older adults | _J Oleo Sci_  
**Watanabe 2020** | RCT (Nihon Pharmaceutical) | Plasmalogen vs. Prevagen comparison; plasmalogen group showed cognitive benefit | _J Oleo Sci_  
**Smith et al. 2025** | First-in-human PK study (PPI-1011) | Safety, tolerability confirmed for synthetic precursor | _Clin Transl Sci_. doi:[10.1111/cts.70195](https://doi.org/10.1111/cts.70195)  
  
### Animal Model Evidence

  * **Plasmalogen-deficient mice:** Neuromuscular junction defects, cognitive impairment, reduced lifespan (Dorninger et al. 2017)
  * **Parkinson's model:** Intranasal plasmalogen nanomedicine improved dopaminergic neuron survival (Wu et al. 2024, _Adv Healthc Mater_)
  * **Alzheimer's model:** DHA-AAG reduced Aβ 1-42 and improved memory in APP-transgenic mice (Wood et al. 2011)
  * **Cardiac dysfunction:** Alkylglycerol supplementation restored cardiac plasmalogens and mitochondrial function in dilated cardiomyopathy mice (2025 study)
  * **C. elegans lifespan:** Plasmalogen supplementation extended lifespan (suggesting geroprotective potential)



* * *

## Doses in studies

### Commercial Products

Product | Manufacturer | Form | Composition | Cost Range  
---|---|---|---|---  
**ProdromeGlia** | Prodrome Sciences (Goodenowe) | Oral liquid | DHA-AAG plasmalogen precursor | ~$150-200/month  
**ProdromeBrain** | Prodrome Sciences | Oral liquid | DHA-AAG (higher dose) | ~$200-300/month  
**Daiwa Brain Health** | Daiwa | Capsules | 0.5 mg plasmalogen/capsule | ~$50-80/month  
**Nihon Seiken** | Nihon Pharmaceutical | Capsules | Purified plasmalogens (ascidian source) | Japan market  
**Alkylglycerol (shark liver oil)** | Various | Oil/softgel | Natural alkylglycerols (precursors) | ~$20-40/month  
  
> ⚠️ **Quality concern:** Products vary enormously in bioactive plasmalogen/precursor content. The Goodenowe DHA-AAG formulation is the most clinically validated but also the most expensive and associated with regulatory controversy (see below).

### Blood Testing

  * **ProdromeScan (Prodrome Sciences):** Blood test measuring ethanolamine plasmalogen species (DHA-PL, AA-PL) vs. phosphatidyl species
  * **Report:** Provides DHA-PL/(LA+AA)-PE ratio — the key aging/disease biomarker
  * **Cost:** ~$200-300
  * **Clinical availability:** Direct-to-consumer; not standard lab test



* * *

## Regulatory and Ethical Concerns

### FDA Warning (January 2025)

The FDA issued a warning letter to Goodenowe's clinic stating that a supplement study **failed to file the required Investigational New Drug (IND) application**. The FDA wrote that this failure: \- "Raises significant concerns about the safety and welfare of enrolled subjects" \- "Raises concerns about the validity and integrity of the data collected"

> **Assessment:** Plasmalogen biochemistry and deficiency associations are legitimate and well-established. Goodenowe's original scientific work identifying the deficiency is sound. However, the clinical program has been **marred by regulatory non-compliance and commercial conflicts of interest**. The preclinical data for Parkinson's and age-related cognitive decline is promising but requires independent replication through proper IND-governed trials.

### Key Concerns

  1. **Founder bias:** Goodenowe founded Prodrome Sciences (sells supplements and tests) — inherent conflict of interest
  2. **No independent RCTs:** The main clinical evidence comes from Goodenowe-affiliated researchers
  3. **Open-label designs:** No placebo-controlled trials published to date
  4. **Cost barriers:** Products are expensive ($150-300/month for clinical doses)
  5. **Safety profile:** Short-term safety appears good, but no long-term (>1 year) safety data exists



* * *

## Evidence Quality Summary

Evidence Type | Status | Rating  
---|---|---  
**Plasmalogen decline in aging (epidemiological)** | Multiple cohorts, Framingham data | **Strong**  
**Association with cognitive decline** | Robust, reproducible across labs | **Strong**  
**Mechanism (antioxidant, membrane)** | In-vitro and animal data solid | **Strong**  
**Supplementation PK (blood levels)** | One open-label trial, dose-dependent | **Moderate**  
**Cognitive benefit of supplementation** | Open-label, 41% improved | **Preliminary**  
**Independent RCTs** | None published | **Absent**  
**Long-term safety** | No data | **Unknown**  
  
* * *

## Sources

1. Goodenowe DB, Haroon J, Kling MA, et al. Targeted plasmalogen supplementation: effects on blood plasmalogens, oxidative stress biomarkers, cognition, and mobility in cognitively impaired persons. Front Cell Dev Biol . 2022;10:864842. PMID: 35874835 . doi: 10.3389/fcell.2022.864842 (DOI 10.3389/fcell.2022.864842, PubMed 35874835)
2. NCT04484454 (NCT04484454)
3. Smith T, Knudsen KJ, Ritchie SA. (2025). First-in-human safety, tolerability, and pharmacokinetics of PPI-1011, a synthetic plasmalogen precursor. Clin Transl Sci . 18. doi: 10.1111/cts.70195 (DOI 10.1111/cts.70195)
4. Dorninger F, et al. (2017). Plasmalogen deficiency in mice causes neuromuscular junction defects. Dorninger et al. PMID: 28108285 (PubMed 28108285)
5. Wu Y, et al. (2024). Lipid and transcriptional regulation in a Parkinson's disease mouse model by intranasal plasmalogen nanomedicines. Adv Healthc Mater . 13:2304588. doi: 10.1002/adhm.202304588 (DOI 10.1002/adhm.202304588)
6. Sindelar PJ, et al. (1999). Plasmalogens and oxidative stress: the vinyl ether bond as a sacrificial antioxidant target. Sindelar et al. PMID: 10456357 (PubMed 10456357)